{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:50:23Z","timestamp":1766181023344,"version":"3.37.3"},"reference-count":25,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Background\/Aims<\/jats:title><jats:p>To evaluate predictive factors for the treatment success of ocriplasmin and to use these factors to generate a multivariate model to calculate the individual probability of successful treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were collected in a retrospective, multicentre cohort study. Patients with vitreomacular traction (VMT) syndrome without a full-thickness macular hole were included if they received an intravitreal injection (IVI) of ocriplasmin. Five factors (age, gender, lens status, presence of epiretinal membrane (ERM) formation and horizontal diameter of VMT) were assessed on their association with VMT resolution. A multivariable logistic regression model was employed to further analyse these factors and calculate the individual probability of successful treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>167 eyes of 167 patients were included. Univariate analysis revealed a significant correlation to VMT resolution for all analysed factors: age (years) (OR 0.9208; 95%\u2009CI 0.8845 to 0.9586; p&lt;0.0001), gender (male) (OR 0.480; 95%\u2009CI 0.241 to 0.957; p=0.0371), lens status (phakic) (OR 2.042; 95%\u2009CI 1.054 to 3.958; p=0.0344), ERM formation (present) (OR 0.384; 95%\u2009CI 0.179 to 0.821; p=0.0136) and horizontal VMT diameter (\u00b5m) (OR 0.99812; 95%\u2009CI 0.99684 to 0.99941, p=0.0042). A significant multivariable logistic regression model was established with age and VMT diameter.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Known predictive factors for VMT resolution after ocriplasmin IVI were confirmed in our study. We were able to combine them into a formula, ultimately allowing the calculation of an individual probability of treatment success with ocriplasmin in patients with VMT syndrome without FTHM.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-310874","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T16:17:52Z","timestamp":1509466672000},"page":"1092-1097","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study"],"prefix":"10.1136","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6458-0302","authenticated-orcid":false,"given":"Christoph","family":"Paul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Heun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Helge","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Feltgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Wachtlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Kaymak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Mennel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Janusz","family":"Koss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Fauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias M","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricarda G","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petrus","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Schmitz-Valckenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Kazerounian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Szurman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bertelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,10,31]]},"reference":[{"key":"2020050713014871000_102.8.1092.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.07.042"},{"key":"2020050713014871000_102.8.1092.2","unstructured":"FDA. Center for drug evaluation and research. 2012 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125422Orig1s000Approv.pdf"},{"key":"2020050713014871000_102.8.1092.3","unstructured":"EMA. EPAR summary for the public. 2013 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/002381\/WC500142159.pdf"},{"key":"2020050713014871000_102.8.1092.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110823"},{"key":"2020050713014871000_102.8.1092.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.045"},{"key":"2020050713014871000_102.8.1092.6","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00417-016-3363-5","article-title":"Ocriplasmin use for vitreomacular traction and macular hole: a meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications","volume":"254","author":"Chatziralli","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2020050713014871000_102.8.1092.7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3928\/23258160-20160808-04","article-title":"Baseline predictors of vitreomacular adhesion\/traction resolution following an intravitreal injection of ocriplasmin","volume":"47","author":"Jackson","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2020050713014871000_102.8.1092.8","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00347-015-0073-z","article-title":"[Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences]","volume":"112","author":"Maier","year":"2015","journal-title":"Ophthalmologe"},{"key":"2020050713014871000_102.8.1092.9","doi-asserted-by":"crossref","unstructured":"Steel DH , Wong D . Ocriplasmin - variable efficacy? Graefe\u2019s archive for clinical and experimental ophthalmology. Germany: Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016:1245\u20136.","DOI":"10.1007\/s00417-016-3404-0"},{"key":"2020050713014871000_102.8.1092.10","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00417-017-3657-2","article-title":"The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study","volume":"255","author":"Bertelmann","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2020050713014871000_102.8.1092.11","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182a15f8b"},{"key":"2020050713014871000_102.8.1092.12","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-304961"},{"key":"2020050713014871000_102.8.1092.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)73813-9"},{"key":"2020050713014871000_102.8.1092.14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3928\/23258160-20151008-09","article-title":"Post-market experience with ocriplasmin including chronic electrophysiologic changes","volume":"46","author":"Small","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2020050713014871000_102.8.1092.15","unstructured":"Ziemssen F , Bartz-Schmidt KU , Dimopoulos S . Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when? Graefe\u2019s archive for clinical and experimental ophthalmology. Germany: Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016:615\u20136."},{"key":"2020050713014871000_102.8.1092.16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00417-015-3031-1","article-title":"Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study","volume":"254","author":"Chatziralli","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2020050713014871000_102.8.1092.17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/IAE.0000000000000755","article-title":"Resolution of subretinal fluid and outer retinal changes in patients treated with ocriplasmin","volume":"36","author":"Nudleman","year":"2016","journal-title":"Retina"},{"key":"2020050713014871000_102.8.1092.18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ajo.2015.01.034","article-title":"Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes","volume":"159","author":"Sharma","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2020050713014871000_102.8.1092.19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2014.09.015","article-title":"Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin","volume":"159","author":"Warrow","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2020050713014871000_102.8.1092.20","first-page":"909","article-title":"[Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin]","volume":"231","author":"Lommatzsch","year":"2014","journal-title":"Klin Monbl Augenheilkd"},{"key":"2020050713014871000_102.8.1092.21","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304219"},{"key":"2020050713014871000_102.8.1092.22","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.ophtha.2016.06.043","article-title":"Results of the 2-year ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS) randomized trial","volume":"123","author":"Dugel","year":"2016","journal-title":"Ophthalmology"},{"key":"2020050713014871000_102.8.1092.23","doi-asserted-by":"crossref","unstructured":"Feng HL , Roth DB , Hasan A , et al . Intravitreal ocriplasmin in clinical practice: predictors of success, visual outcomes, and complications. Retina 2017.doi:10.1097\/IAE.0000000000001505","DOI":"10.1097\/IAE.0000000000001505"},{"key":"2020050713014871000_102.8.1092.24","doi-asserted-by":"crossref","unstructured":"Paul C , Heun C , Muller HH , et al . Impact of vitreoretinal interface architecture on successful vitreomacular traction resolution in eyes scheduled for intravitreal ocriplasmin therapy. Retina 2016.","DOI":"10.1097\/IAE.0000000000001371"},{"key":"2020050713014871000_102.8.1092.25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/IAE.0000000000000508","article-title":"Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion\/vitreomacular traction, including when associated with macular hole","volume":"35","author":"Gandorfer","year":"2015","journal-title":"Retina"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:55:54Z","timestamp":1601110554000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,31]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,19]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310874"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310874","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"type":"print","value":"0007-1161"},{"type":"electronic","value":"1468-2079"}],"subject":[],"published":{"date-parts":[[2017,10,31]]}}}